November 6, 2020
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Attention: David Gessert
Re: | Neurotrope Bioscience, Inc. | |
Registration Statement on Form S-1 | ||
File No. 333-249434 | ||
Acceleration Request |
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the Securities and Exchange Commission (the “Commission”) promulgated under the Securities Act of 1933, as amended, Neurotrope Biocience, Inc. (“Neurotrope Bioscience”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-249434), as amended (the “Registration Statement”), be accelerated to 4:30 p.m. Eastern Time, on Monday, November 9, 2020.
Neurotrope Bioscience requests that it be notified of the effectiveness of the Registration Statement on Form S-1 by telephone call to its counsel Jeffrey P. Schultz at (212) 692-6732, followed by written confirmation to the addresses listed on the cover page of the Registration Statement. Thank you for your attention to this matter.
[Signature page follows]
Very truly yours,
| |||
NEUROTROPE BIOCIENCE, INC. |
By: |
/s/ Robert Weinstein | |
Name: | Robert Weinstein | |
Title: | Chief Financial Officer | |
cc: | Securities and Exchange Commission |
Eric Envall
Franklin Wyman
Brian Cascio
David Gessert
Neurotrope Bioscience, Inc.
Robert Weinstein
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Kenneth R. Koch, Esq.